Abstract
AbstractThe neuropharmacology of tefludazine, a new neuroleptic with phenylindan structure, has been investigated in comparison with cis(Z)‐flupentixol, fluphenazine, haloperidol, methiothepin, thioridazine, and clozapine. Tefludazine showed potent dopamine (DA) antagonistic activity in a broad range of test models in vitro and in vivo in mice, rats, and dogs (receptor binding, antagonism of DA agonist‐induced behavior, inhibition of conditioned avoidance, catalepsy, etc.). High oral activity and long duration of action was found. Interestingly, the cataleptogenic potency at the time of peak effect was seven times weaker than the antistereotypic activity, in contrast with that observed with cis(Z)‐flupentixol, fluphenazine, and haloperidol. In addition to DA antagonism, tefludazine was equipotent at 5‐HT receptors (in vitro receptor binding, 5‐HT antagonism in isolated peripheral tissue, cardiovascular 5‐HT antagonism, antagonism of I‐5‐HTP‐ and 5‐MeODMT‐induced behaviors). No antimuscarinic and low α‐adrenoceptor blocking effect was found in pithed rats and in denervated cat nictitating membrane preparation. The DA/5‐HT activity profile of tefludazine resembled that of methiothepin, which, however, had potent α‐adrenoceptor blocking effect. It is concluded that tefludazine has a neuropharmacological profile that should combine antipsychotic potential with lower risk of extrapyramidal symptoms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.